Abstract
Allergic rhinitis is a chronic inflammatory disorder of the nasal passages. It affects approximately 20% of the population, is a significant health and economic burden, and severely impairs quality of life. Two main instruments, Medical Outcomes Study 36-Item Short Form health survey (SF-36) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) have been used to assess quality of life in patients with allergic rhinitis. Antihistamines, corticosteroids, anticholinergic agents, decongestants, cromoglycates, and immunotherapy are used to treat patients with allergic rhinitis. Of these, antihistamines and intranasal corticosteroids are the most efficacious and frequently utilised medications. Studies have demonstrated improvements in quality of life with both of these medications in patients with allergic rhinitis.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 891-899 |
| Number of pages | 9 |
| Journal | PharmacoEconomics |
| Volume | 19 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2001 |
Funding
Supported by the Ernest S. Bazley Grant to Northwestern Memorial, Hospital and Northwestern University Medical School, USA.
ASJC Scopus subject areas
- Public Health, Environmental and Occupational Health
- Health Policy
- Pharmacology
